anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Increasing attention to the early stages of psychosis and the identification of symptomatic prodromal states have led to the development of a growing number of screening tools. The 16-item version of the Prodromal Questionnaire (PQ-16) is a worldwide used self-administered tool for this purpose. However, to date, fundamental psychometric properties of PQ-16 were not thoroughly investigated. This study aimed to examine the structural validity, measurement invariance, reliability and other psychometrical properties of the Italian version of the PQ-16 (iPQ-16) in help-seeking individuals and in the general population.
METHODS: The iPQ-16 was administered to 449 young outpatients attending six community mental health services and to 318 control participants enrolled in educational environment. Confirmatory factor analyses (CFAs), measurement invariance (MI) between the help-seeking group and the general population sample, convergent validity, test-retest reliability, internal consistency, and prevalence analyses were performed. Lastly, the validity of the adopted PQ-16 cut-offs through Receiver Operating Characteristic (ROC) curves plotted against CAARMS diagnoses was also tested.
RESULTS: CFAs confirmed the single-factor structure for the iPQ-16 and scalar MI was reached. The iPQ-16 showed high internal consistency, test-retest reliability, convergent validity, and acceptable diagnostic accuracy. ROC analysis suggested a score of ≥4 as best cut-off.
CONCLUSIONS: The iPQ-16 represents a valid and reliable questionnaire for the assessment of high mental risk in both Italian outpatients and general student population. It has good psychometric properties and is easy to implement as UHR screening for clinical as well as research purposes.
The invention provides goose parvovirus (GPV) and applications thereof, and belongs to the technical field of biology. The invention provides a goose parvovirus GPV-YZ strain as well as applications thereof in preparing medicaments for preventing and treating the gosling plague disease. The microorganism preservation number is CGMCC NO.8160. The invention also provides a gosling plague disease viral vaccine as well as an anti-gosling plague yolk antibody. The goose parvovirus YZ strain provided by the invention has favorable immunogenicity for the present epidemic goose parvovirus, can resist toxicity attacking of the GPV-AV240 strain, the GPV-GD strain as well as the toxic strain of the goose parvovirus, and has the protection capability against the GPV-AV240 strain and the GPV-GD strain. After breeding geese are immunized by the gosling plague disease viral vaccine provided by the invention, young geese can be protected by maternal antibodies, and can be prevented from being infected by gosling plague viruses. The anti-gosling plague yolk antibody provided by the invention can prevent and treat gosling disease.
Ricin is a highly toxic plant toxin that can cause multi-organ failure, especially liver dysfunction, and is a potential bioterrorism agent. Despite the serious public health challenge posed by ricin, effective therapeutic for ricin-induced poisoning is currently unavailable. Therefore, it is important to explore the mechanism of ricin poisoning and develop appropriate treatment protocols accordingly. Previous studies have shown that lipid peroxidation and iron accumulation are associated with ricin poisoning. Ferroptosis is an iron-dependent form of cell death caused by excessive accumulation of lipid peroxide. The role and mechanism of ferroptosis in ricin poisoning are unclear and require further study. We investigated the effect of ferroptosis on ricin-induced liver injury and further elucidated the mechanism. The results showed that ferroptosis occurred in the liver of ricin-intoxicated rats, and Ferrostatin‑1 could ameliorate hepatic ferroptosis and thus liver injury. Ricin induced liver injury by decreasing hepatic reduced glutathione and the protein level of glutathione peroxidase 4 and Solute Carrier Family 7 Member 11, increasing iron, malondialdehyde and reactive oxygen species, and mitochondrial damage, whereas Ferrostatin‑1 pretreatment increased hepatic reduced glutathione and the protein level of glutathione peroxidase 4 and Solute Carrier Family 7 Member 11, decreased iron, malondialdehyde, and reactive oxygen species, and ameliorated mitochondrial damage, thereby alleviated liver injury. These results suggested that ferroptosis exacerbated liver injury after ricin poisoning and that inhibition of ferroptosis may be a novel strategy for the treatment of ricin poisoning.
The invention provides a nucleic acid medicine for treating osteoarthritis and application thereof, wherein the application is the application of an agent for silencing or inhibiting LNCRNA LINC01152 expression in preparing a medicine for treating osteoarthritis, and the nucleic acid medicine comprises the agent for silencing or inhibiting LNCRNALINC01152 expression. The invention discovers that inhibiting LNCRNALINC01152 expression can promote the expression of cartilage-forming forward regulatory factor SOX9 and inhibit the activation of inflammatory signal pathway NF-Kb. In vivo experiments also demonstrated that inhibiting LNCRNALINC01152 expression can increase bone volume/total volume (BV/TV), bone density (BMD) and small Liang Shuliang (tb.t), reducing trabecular separation (tb.sp). It is demonstrated that inhibition of LNCRNALINC01152 expression promotes chondrogenic differentiation, resulting in repair of defective subchondral bone, thereby alleviating osteoarthritis. Therefore, agents targeted to inhibit LNCRNALINC01152 can be used to prepare nucleic acid pharmaceuticals for the treatment of osteoarthritis. The invention provides an important new target point for developing new medicines for osteoarthritis.
Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
<P>PROBLEM TO BE SOLVED: To provide an external preparation for the skin, obtained by solving the problems associated with astringency of a protein possessed by proanthocyanidin without damaging the effects of the proanthocyanidin on a living body.  <P>SOLUTION: The external preparation for the skin contains the proanthocyanidin and a proteolytic peptide having ≤7,000 average molecular weight. The proanthocyanidin preferably contains ≥1 pt.wt. a dimeric to tetrameric proanthocyanidin based on 1 pt.wt. a pentameric proanthocyanidin in or more.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Several epidemiological studies and therapeutic observations in the complementary and alternative medicine (CAM) literature suggest that diet is key to development of CD and its treatment. The investigators took advantage of these CAM recommendations and designed dietary interventions. Our preliminary open label studies in IBD patients showed that our interventions are acceptable and well-tolerated and result in improvement, reducing symptoms and/or the degree of inflammation. The investigators are now seeking to validate this finding and determine the mechanisms underlying the effects of dietary manipulation-such as potential effects on colonic bacterial microflora. In another pilot study using 16s rDNA bacterial fingerprinting, the investigators demonstrated that the intestinal microflora of patients with CD differ significantly from healthy individuals. Whether the investigators can normalize/change the microflora of CD patients with dietary therapies, however, remains to be determined. Accordingly, the investigators designed a double blind placebo controlled study to test the hypotheses that: (1) dietary manipulation with either diet or a FOS supplement is an effective CAM therapy that prevents CD relapse (leads to maintenance of remission) and (2) such dietary manipulation can normalize the microflora of CD patients and decrease mucosal oxidative damage.

90 participants are expected to undergo the trial and have a 2:1 chance of receiving active therapy. The trial is seeking to enroll participants with inactive CD who have been medically induced into remission within 9 months of enrollment. Participants must be on their Crohn's medications at a stable dose for 3 months, which does not include steroids (e.g. Prednisone, Entocort) or antibiotics at the time of enrollment. Participants will be followed till relapse occurs or up to 52 weeks. Participants are asked to fill out a variety of questionnaires, keep a food and adverse event diary, and have a research, limited, unprepped flexible sigmoidoscopy for colonic tissue collection at the beginning and end of the study period.

Significance. This study could provide information to suggest diet or dietary supplement as a safe therapy for IBD and lay the groundwork for more definitive, randomized, controlled trials.
PURPOSE: Investigating the causes of visual loss and the best corrected visual acuity (BCVA) is crucial for identifying avoidable eye problems and planning appropriate rehabilitation and assistive technology (AT) services. The study aimed to identify various causes of vision loss and determine AT required for vision rehabilitation (VR).
METHODS: The electronic records of patients who attended the VR clinic at a tertiary eyecare for the past 2 years were reviewed. Information such as demographics, BCVA, and causes of visual impairment were retrieved from the records. BCVA was categorized into better than or equal to 1/60 and less than <1/60 for AT services.
RESULTS: In total, 1723 patients, mostly male (71.2%), visited the rehabilitation clinic from 2018 to 2019. Around 58.6% of patients belonged to the age group 16-49 years, whereas 25.6% were less than 15 years old. The most frequent eye problems were retinal disorders (63.5%), followed by retinitis pigmentosa (15.2%) and rod-cone dystrophy (4.7%). In contrast, congenital disorders were the most common cause of vision loss among younger groups. Approximately 36.0% of patients had <1/60 blindness and 16.6% had ≥1/60. Around 17.1% of patients would benefit from large prints (near vision acuity N18-N12).
CONCLUSION: Early detection and timely management will prevent a significant proportion of patients from developing irreversible vision loss. Around one-third of patients would benefit from visual substitution AT.
Postoperative spinal surgical site infections (SSI) have a significant effect on patient morbidity and mortality.1 Spinal SSI as well as other complications including pseudoarthrosis occur at a higher rate in patients with comorbidities including obesity, smoking history, diabetes, steroid use, older age, and higher modified frailty index.2 Patients of Veterans Affairs (VA) medical centers have higher number of comorbidities than non-VA patients, and are therefore at higher risk for postoperative spinal SSI and complications.3,4 Spinal SSI has been reported to be anywhere from \<1% in decompressions to \>10% after instrumented fusion.5 Anecdotal evidence has suggested SSI to be as high as 20% among our population. As spine surgeons for the largest VA in the country, our team sought a product that could reduce the rate of spinal SSI, and ideally result in improved patient outcomes, in our at-risk patient population.

Skye Biologics offers placental tissue-based matrices in the form of both flowable and solid mediums. The flowable matrix has been shown in-vitro to contain significant amounts of collagen and growth factors, as well as molecules known to modulate immune response. The results of this have been in-vitro inhibition of methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus saprophyticus proliferation, increase in migration of adipose-derived stem cells (ASCs), adherence to the ASCs in cultures.6 In translation of these results clinical application has been well received, with various subspecialties including ENT and orthopedics using the products. Based on both the positive in vitro and in vivo results, out team began using the flowable product with good initial subjective results, including improved wound healing and excellent patient satisfaction. The true clinical efficacy remains to be assessed, however. Our team sought to provide level 1 evidence on this product in thoracolumbosacaral posterior spinal decompression and/or fusion in our at-risk population via a single-blinded randomized control trial at high-volume institution (s).
The invention discloses a traditional Chinese medicine composition for treating enterogastritis. The traditional Chinese medicine composition is prepared from houttuynia cordata, clovershrub, hairy euphorbia, sticktight, rhizoma atractylodis, pericarpium arecae, costustoot, sugar cane juice and EM original liquid. The traditional Chinese medicine composition uses houttuynia cordata mainly for the houttuynia cordata is able to clear away heat and toxic materials, expel pus and carbuncle, remove blood stasis and supplement the heart blood, promote urination and relieve distension, and has multiple antibiotic constituents and is suitable for enterogastritis with damp and hot type swelling pain. Clovershrub, hairy euphorbia and sticktight can clear heat, promote diuresis and detoxify, relieve rheumatic pains, invigorate the circulation of blood, stop diarrhea and pain, and is good at sterilizing and treating enterogastritis. Hizoma atractylodis, pericarpium arecae, and costustoot are good for drying damp and strengthening spleen, descending Qi and loosening the center, regulating middle energizer and removing stagnancy, and treating the chest lumpy and windy damp and hot turbidite and borborygmus. The pericarpium arecae can promote urination, relieve distension, and descend qi and treat cold and hot Qi, and dredge small and large intestines and discharge poison of wet and hot, and harmonize stomach, tonify spleen, whet the appetite and regulate middle energizer; through the synergistic effect of the formula, the drugs reach the excellent effect of treating the enterogastritis with unclear damp and hot, stomachache and defecation for many times.
PURPOSE: A composition for treating cartilage damage containing 97 %v/v of moisture is provided to absorb shock by injecting into body, and to prevent dissolution by inflammatory reaction or toxic materials without cytotoxicity. CONSTITUTION: A composition for treating cartilage damage contains demineralized bone particle (DBP) gel and a costal chondrocyte composition. The DBP is derived from mammalian bone. The particle size of the DBP is 10-300 micrometer. The weight ratio of the DBP is 5-20 wt%. The composition has pH 6-7.
<P>PROBLEM TO BE SOLVED: To obtain an antisense nucleotide which can effectively inhibit apoptosis of Chinese hamster ovary (CHO) cells by effectively suppressing the expression of caspase-3 related to apoptosis and an expression vector thereof and to provide an inhibition method of apoptosis in which the quality of target protein produced in the recombinant cells can be enhanced.  <P>SOLUTION: This antisense nucleotide is used for suppressing the expression of caspase-3 and comprises a specific base sequence. This expression vector contains the antisense nucleotide and expresses antisense RNA of caspase-3. This inhibition method of apoptosis of recombinant cells comprises introducing the expression vector into the recombinant cells and suppressing the expression of caspase-3. Therefore, apoptosis can be inhibited by effectively suppressing the expression of caspase-3 related to apoptosis and the quality of target protein produced in the recombinant cells can be enhanced by inhibiting apoptosis.  <P>COPYRIGHT: (C)2003,JPO
Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating TRACLEER, monthly during treatment and one month after stopping treatment with TRACLEER. The patient should contact her physician immediately for pregnancy testing if onset of menses is delayed or pregnancy is suspected. If the pregnancy test is positive, the physician and patient must discuss the risks to her, the pregnancy, and the fetus.

Contraception

Drug interaction studies show that bosentan reduces serum levels of the estrogen and progestin in oral contraceptives. Based on these findings, hormonal contraceptives (including oral, injectable, transdermal, and implantable contraceptives) may be less effective for preventing pregnancy in patients using TRACLEER and should not be used as a patient's only contraceptive method [see Drug Interactions (7.2)] . Females of reproductive potential using TRACLEER must use two acceptable methods of contraception during treatment and for 1 month after treatment with TRACLEER. Patients may choose one highly effective form of contraception (intrauterine devices (IUD) or tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods). If a partner's vasectomy is the chosen method of contraception, a hormone or barrier method must be used along with this method. Counsel patients on pregnancy planning and prevention, including emergency contraception, or designate counseling by another healthcare provider trained in contraceptive counseling [see Boxed Warning] . 

Infertility

Males

Decreased sperm counts have been observed in patients receiving TRACLEER. Based on these findings and findings in animals, TRACLEER may impair fertility in males of reproductive potential. It is not known whether effects on fertility would be reversible [see Warnings and Precautions (5.6), Adverse Reactions (6.1), Nonclinical Toxicology (13.1)] .
A method is provided for inhibiting or preventing adherence of cancer cells or immunocytes to their target cells or target tissues by reducing the level of activity of FX enzyme in the cells. The reduction may either be in the amount of the FX protein or in the enzymatic activity of the protein in the cells. In addition, methods and agents are provided for down-regulating or up-regulating the level of activity of FX in cancer cells and in immunocytes. The down-regulation of FX in cancer cells is provided for inhibiting or preventing metastasis of cancer cells and the up-regulation of FX activity in cancer cells is useful for increasing the immunogenicity of these cells when used in a cancer vaccine. Down-regulation of FX in immunocytes inhibits or prevents conditions such as undesired inflammatory responses, auto-immunity and transplant rejection. Up-regulation of FX activity in immunocytes is useful for enhancing an immune reaction in cases of reduced immunity of an individual. The regulation of the level of activity of FX in cancer cells and immunocytes may be achieved by contacting the cells with various agents such as antibodies, growth factors, cytokines or various combinations of such agents. The level of activity of FX in cancer cells is also used as a diagnostic and prognostic factor of metastasis and the level of activity of FX in immunocytes is used as a marker of activation useful in determining an individual's response to an immunogen. Regulation of the level of activity of FX in various cancer cells and activated lymphocytes using an FX antisense sequence enables also to effect the level of various selectin ligands on these cells.
B cell acute lymphoblastic leukemia (B-ALL) arises from genetic alterations impacting B cell progenitors, ultimately leading to clinically overt disease. Extensive collaborative efforts in basic and clinical research have significantly improved patient prognoses. Nevertheless, a subset of patients demonstrate resistance to conventional chemotherapeutic approaches and emerging immunotherapeutic interventions. This review highlights the mechanistic underpinnings governing B-ALL transformation. Beginning with exploring normative B cell lymphopoiesis, we delineate the influence of recurrent germline and somatic genetic aberrations on the perturbation of B cell progenitor differentiation and protumorigenic signaling, thereby facilitating the neoplastic transformation underlying B-ALL progression. Additionally, we highlight recent advances in the multifaceted landscape of B-ALL, encompassing metabolic reprogramming, microbiome influences, inflammation, and the discernible impact of socioeconomic and racial disparities on B-ALL transformation and patient survival.
INTRODUCTION: Low vision has a significant global health problem that impacts the personal, economical, psychological, and social life of an individual. Each year around 684 000 individuals die from falls, 80% of these deaths occur are in low- and middle-income countries. The risk of falling significantly increases with visual impairment. This review aimed to determine the global pooled prevalence of fall and associated factors among individuals with low vision.
METHODS AND MATERIALS: Systematic search of published studies done on PubMed, EMBASE, MEDLINE, Cochrane, Scopus, Web of Science CINAHL and, Google Scholar. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used to report the findings. Quality of studies was assessed using the modified Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using a random-effects method using the STATA™ Version 14 software.
RESULT: Thirty-five (35) studies from different regions involving 175,297 participants included in this meta-analysis. The overall pooled global prevalence fall among individual with low vision was17.7% (95% CI: 16.4-18.9) whereas the highest prevalence was 35.5%; (95% CI: 28.4-42.5) in Australia and the lowest was 19.7%; (95% CI: 7.6-31.8) seen in South America. Fear of falling (OR: 0.16(95%CI 0.09-0.30), and severity of visual impairment (OR: 0.27(95%CI (0.18-0.39) increases the odds of falling.
CONCLUSION: As one cause of accidental death, the prevalence of falls among individuals with low vision is high. Fear of falling and severity of falling increases the odds of falling. Different stakeholders should give due attention and plan effective strategies to reduce the fall among this population.
The present invention relates to a photosensitizer based on aqueous porphyrin-fullerene conjugates and a preparation method thereof. More specifically, the present invention relates to triethylene glycol-porphyrin-fullerene polymer resulting from the binding of TEG-porphyrin synthesized by binding porphyrin with triethylene glycol dendron with fullerene and to a method of preparing an aqueous photodynamic diagnostic or therapeutic photosensitizer. According to the present invention, the porphyrin photosensitizer incorporated with triethylene glycol dendron has an enhanced dispersibility in water compared to conventional photosensitizers. Again, the triethylene glycol dendron-porphyrin photosensitizers are incorporated with fullerene, and the porphyrin results in the quenching of electromigration generated when the porphyrin absorbs light and thus, the porphyrin can turn on and off the function thereof in vivo using ester bond and hydrolase. Furthermore, the photosensitizer reacts to the light with longer-wavelength compared to conventional photosensitizers and can generate active oxygen actively as both porphyrin and fullerene can generate active oxygen. Also, the porphyrin has common characteristics like other light absorbing materials and can be utilized as a light conversion material and a bio-imaging material.